U.S. Markets closed

Complimentary Technical Snapshots on Aquinox Pharma and Three More Healthcare Stocks

Stock Research Monitor: PRGO, RHE, and AMRX

LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AQXP sign up now at www.wallstequities.com/registration. On Monday, July 23, 2018, US markets sawsixout of nine sectors finishing the day inred and three in green. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 7,841.87, up 0.28%; the Dow Jones Industrial Average edged 0.06% lower, to finish at 25,044.29; and the S&P 500 closed at 2,806.98, up 0.18%. This Tuesday morning, WallStEquities.com looks at the performance of these four Healthcare stocks: Perrigo Co. PLC (NYSE: PRGO), Regional Health Properties Inc. (NYSE AMER: RHE), Amneal Pharmaceuticals Inc. (NYSE: AMRX), and Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP). All you have to do is sign up today for this free limited time offer by clicking the link below.



On Monday, shares in Dublin, Ireland headquartered Perrigo Co. PLC recorded a trading volume of 974,544 shares. The stock ended the session 0.71% higher at $76.51. The Company's shares have gained 1.54% in the last month. The stock is trading above its 50-day moving average by 1.82%. Moreover, shares of Perrigo, which manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 53.59.

On July 12th, 2018, research firm Goldman downgraded the Company's stock rating from 'Neutral' to 'Sell'. Get the full research report on PRGO for free by clicking below at:


Regional Health Properties

Suwanee, Georgia headquartered Regional Health Properties Inc.'s stock closed the day 3.53% lower at $0.23 with a total trading volume of 184,080 shares. The Company's shares have advanced 5.91% in the past month. The stock is trading below its 50-day moving average by 2.10%. Additionally, shares of the Company, which through its subsidiaries, operates as a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transaction, have an RSI of 48.52. Access the free research report on RHE now by signing up at:


Amneal Pharmaceuticals

Shares in Amneal Pharmaceuticals Inc. recorded a trading volume of 1.98 million shares, which was above their three months average volume of 1.40 million shares. The stock ended yesterday's trading session 4.05% higher at $19.27. The Company's shares have advanced 13.02% in the past month. The stock is trading above its 50-day and 200-day moving averages by 8.23% and 3.52%, respectively. Furthermore, shares of Amneal Pharma, which manufacture and commercialize complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, have an RSI of 66.13.

On July 23rd, 2018, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock, with a target price of $22 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AMRX at:


Aquinox Pharmaceuticals

Vancouver, Canada headquartered Aquinox Pharmaceuticals Inc.'s stock finished Monday's session 2.99% higher at $3.10 with a total trading volume of 855,302 shares, which was above their three months average volume of 794.34 thousand shares. The stock is trading below its 50-day moving average by 69.49%. Additionally, shares of Aquinox Pharma, which engages in developing novel therapeutics for chronic urological conditions by inflammation and pain, have an RSI of 27.87. Aspiring Member, please take a moment to register below for your free research report on AQXP at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities